Axsome Therapeutics Files 8-K

Ticker: AXSM · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1579428

Axsome Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAxsome Therapeutics, INC. (AXSM)
Form Type8-K
Filed DateJun 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: AXSM

TL;DR

AXSM filed a standard 8-K, no major news.

AI Summary

Axsome Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting other events and financial statements. The filing does not contain specific details on new events, financial figures, or material agreements, but serves as a standard regulatory update.

Why It Matters

This filing is a routine regulatory update from Axsome Therapeutics, Inc. and does not appear to contain material new information for investors at this time.

Risk Assessment

Risk Level: low — The filing is a routine 8-K and does not disclose any new material events, risks, or financial information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a Current Report for Axsome Therapeutics, Inc., reporting on 'Other Events' and 'Financial Statements and Exhibits' as of June 9, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is June 09, 2025.

Where is Axsome Therapeutics, Inc. incorporated?

Axsome Therapeutics, Inc. is incorporated in Delaware.

What is the Commission File Number for Axsome Therapeutics, Inc.?

The Commission File Number for Axsome Therapeutics, Inc. is 001-37635.

What is the address of Axsome Therapeutics, Inc.'s Principal Executive Offices?

The address of Axsome Therapeutics, Inc.'s Principal Executive Offices is One World Trade Center, 29th Floor, New York, New York, 10007.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding Axsome Therapeutics, Inc. (AXSM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing